BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12563241)

  • 1. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS
    Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
    Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of established human breast tumors to vaccination with mammaglobin-A cDNA.
    Narayanan K; Jaramillo A; Benshoff ND; Campbell LG; Fleming TP; Dietz JR; Mohanakumar T
    J Natl Cancer Inst; 2004 Sep; 96(18):1388-96. PubMed ID: 15367572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
    Bharat A; Benshoff N; Fleming TP; Dietz JR; Gillanders WE; Mohanakumar T
    Breast Cancer Res Treat; 2008 Aug; 110(3):453-63. PubMed ID: 17874294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
    Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
    Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
    Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
    Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
    Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells.
    Rentzsch C; Kayser S; Stumm S; Watermann I; Walter S; Stevanoviç S; Wallwiener D; Gückel B
    Clin Cancer Res; 2003 Oct; 9(12):4376-86. PubMed ID: 14555509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of mammaglobin-A-specific CD4 T cells and identification of candidate CD4 epitopes for breast cancer vaccine strategies.
    Viehl CT; Frey DM; Phommaly C; Chen T; Fleming TP; Gillanders WE; Eberlein TJ; Goedegebuure PS
    Breast Cancer Res Treat; 2008 May; 109(2):305-14. PubMed ID: 17653857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells.
    Viehl CT; Tanaka Y; Chen T; Frey DM; Tran A; Fleming TP; Eberlein TJ; Goedegebuure PS
    Breast Cancer Res Treat; 2005 Jun; 91(3):271-8. PubMed ID: 15952060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of HLA-A3-restricted CD8+ T cell epitopes derived from mammaglobin-A, a tumor-associated antigen of human breast cancer.
    Jaramillo A; Majumder K; Manna PP; Fleming TP; Doherty G; Dipersio JF; Mohanakumar T
    Int J Cancer; 2002 Dec; 102(5):499-506. PubMed ID: 12432553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
    Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
    Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Full-length dominant-negative survivin for cancer immunotherapy.
    Pisarev V; Yu B; Salup R; Sherman S; Altieri DC; Gabrilovich DI
    Clin Cancer Res; 2003 Dec; 9(17):6523-33. PubMed ID: 14695157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
    Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
    Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.